Quick Answer
Kura Oncology, Inc. reported Long-Term Debt of $9.71 million for fiscal year 2025.
Kura Oncology, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $9.71M | +40.4% |
| 2024 | $6.92M | -25.9% |
| 2023 | $9.33M | +1.9% |
| 2022 | $9.16M | +115.5% |
| 2020 | $4.25M | -41.4% |
| 2019 | $7.25M | -3.3% |
| 2018 | $7.50M | +34.7% |
| 2017 | $5.57M | -24.0% |
| 2016 | $7.32M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.34M | -31.2% | -18.0% |
| June 30, 2025 | $6.51M | -24.1% | -14.9% |
| March 31, 2025 | $7.65M | -18.4% | +10.6% |
| December 31, 2024 | $6.92M | -25.9% | -10.8% |
| September 30, 2024 | $7.76M | -16.5% | -9.5% |
| June 30, 2024 | $8.58M | -7.2% | -8.5% |
| March 31, 2024 | $9.38M | +1.9% | +0.5% |
| December 31, 2023 | $9.33M | +1.9% | +0.5% |
- Kura Oncology, Inc. showed an increase of +40.4% in Long-Term Debt compared to the prior fiscal year.
- Over the 2016–2025 period, Kura Oncology, Inc.’s long-term debt has grown by 32.6% (from $7.32 million to $9.71 million).
- The most recent figure is from Kura Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: